Inside Innovation

Washington’s life science industry is thriving. In 2021 so far, almost 50 biotech companies have gone public across the U.S., with several headquartered in the

This week, Life Science Washington announced its president and CEO, Dr. Leslie Alexandre, will retire at the end of 2021. “Dr. Alexandre has been instrumental

Several Seattle-area vaccine scientists shifted their studies to focus on COVID-19 research in the past 18 months. This field of study continues to build on

Icosavax stocks are performing well amidst the Seattle-based companies new public offering. On its first day as a publicly traded company, Icosavax shares skyrocketed by

Just over a year after going public, Absci stocks are continuing to grow. The Vancouver, Washington based company now is valued at almost $2 billion.

Eliem Therapeutics, a Redmond, Washington based biotech company has filed for IPO. The filing follows two rounds of funding which took place earlier in 2021,

Lumen Bioscience, a Seattle-based biotech company announced it will be expanding its operations and moving to Seattle’s Wallingford neighborhood to continue manufacturing proteins found in

In a growing IPO market, AbSci, Vancouver, A Washington-based biotech company prepares for a public offering, joining additional Washington state biotech startups in the public

Funding from VCs for Seattle’s life science industry grew 266% during Q1 2021 in comparison with Q1 last year. This makes Seattle the fastest-growing life

Earlier this month, Icosavax, a Seattle-based biotech company that originally launched from the University of Washington, filed for IPO. Founded in 2017, Icosavax develops vaccines

Seattle continues to be an integral player in the fight against COVID-19, with local company HDT Bio announcing it will enter early-stage clinical trials in

Absci, a Vancouver-based startup, is the latest Washington biotech company to announce its intent to go public. The company has had a robust 2021 so